Xingchen Peng
West China Hospital · Study Principal Investigator · The West China Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
38
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
295
PubMed author-name match
Trials
Studies that name Xingchen Peng as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:12 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07740993 · A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland CarcinomaWest China Hospital · not yet recruiting · Sebaceous Gland Carcinoma · principal investigator
- Ph2NCT07704372 · Superoxide Dismutase Skin Spray for the Prevention of Acute Radiation Dermatitis in Head and Neck CancerWest China Hospital · recruiting · Radiation-induced Dermatitis · principal investigator
- Ph1NCT07562815 · Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid TumorsWest China Hospital · not yet recruiting · Cancer · principal investigator
- Ph1NCT07545967 · Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After RadiotherapyWest China Hospital · recruiting · Head and Neck Squamous Cell Carcinoma HNSCC · principal investigator
- Ph1NCT07510308 · Clinical Study of MSH2-/- Tumor Cell Vaccines for Advanced pMMR Colorectal Cancer PatientsWest China Hospital · recruiting · pMMR/MSS Advanced Colorectal Cancer · principal investigator
- Ph1NCT07457281 · GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm StudyWest China Hospital · recruiting · Head and Neck Squamous Cell Carcinoma HNSCC · principal investigator
- Ph2/Ph3NCT07353671 · Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation DermatitisWest China Hospital · recruiting · Radiation-induced Dermatitis · principal investigator
- Ph2NCT07339774 · Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.West China Hospital · recruiting · Radiotherapy-induced Oral Mucositis · principal investigator
- Ph1NCT07100210 · A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and ActivityXingchen Peng · recruiting · Refractory Malignant Solid Tumors, mRNA Vaccine, Interleukin · principal investigator
- N/ANCT07086638 · ROS-Scavenging Nanozyme Combined With Thermotherapy Alleviate Radiation Dermatitis in Patients With Head and Neck CancerWest China Hospital · recruiting · Radiation Dermatitis · principal investigator
- N/ANCT07081074 · ROS-scavenging Amino Acid-derived Lipids for the Prevention and Treatment of Radiation Dermatitis in Patients With Head and Neck CancerWest China Hospital · recruiting · Radiation Dermatitis · principal investigator
- N/ANCT07064577 · Novel ROS-scavenging Nanoenzymes for the Treatment of Radiation Dermatitis in Patients With Head and Neck CancerWest China Hospital · recruiting · Radiation Dermatitis · principal investigator
- Ph1NCT07053072 · PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.West China Hospital · recruiting · Liver Cancer · principal investigator
- Ph2NCT07040969 · Spirulina-Derived Product Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck TumorsWest China Hospital · active not recruiting · Radiation-induced Oral Mucositis · principal investigator
- Ph1/Ph2NCT07035249 · DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid TumorsWest China Hospital · recruiting · DCSZ11, Solid Tumors, HNSCC · principal investigator
- N/ANCT07029373 · Plasma Calcitonin Gene-Related Peptide (CGRP) Levels in Patients With Head and Neck Malignancies Undergoing RadiotherapyWest China Hospital · completed · Head and Neck Cancer · principal investigator
- Ph1/Ph2NCT07010120 · A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaWest China Hospital · active not recruiting · HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy · principal investigator
- Ph1NCT06878612 · a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid TumorsXingchen Peng · recruiting · Polyphenols, Cancer Vaccine, Advanced Solid Tumor · principal investigator
- Ph1NCT06741982 · A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV VirusWest China Hospital · withdrawn · HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy · principal investigator
- Ph1NCT06666153 · Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative DiseasesWest China Hospital · not yet recruiting · CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, PTLDs · principal investigator
- Ph1NCT06519552 · A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type IWest China Hospital · recruiting · Mucopolysaccharidosis Type I · principal investigator
- Ph1NCT06494189 · Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous CarcinomaWest China Hospital · completed · Head and Neck Cancer · principal investigator
- N/ANCT06484166 · Efficacy of Fullerene in Preventing Radiation Dermatitis in Patients With Head and Neck Cancer .West China Hospital · completed · Radiation Dermatitis · principal investigator
- Ph2NCT06390176 · Lactobacillus Rhamnosus GG Alleviates Oral Mucositis in Patients Undergoing RadiotherapyWest China Hospital · completed · Oral Mucositis · principal investigator
- N/ANCT06332664 · Collaborative Tele-Nutritional Care for Patient With Stage IV CancerXingchen Peng · completed · Nutrition · principal investigator
- Ph2NCT06285591 · Lactobacillus Reuteri Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck TumorsWest China Hospital · completed · Head and Neck Malignant Tumors · principal investigator
- N/ANCT06272617 · Acupuncture for Prevention and Treatment of Oral-related Complications Caused by Radiotherapy for Head and Neck CancerWest China Hospital · unknown · Malignant Tumor of Head and/or Neck, Radiotherapy; Complications · study director
- Ph1NCT06080984 · The Application of Novel Oncolytic Virus in Late Stage Solid TumorsWest China Hospital · unknown · Malignant Tumor · principal investigator
- Ph2NCT05918224 · Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing RadiotherapyWest China Hospital · completed · Head and Neck Squamous Cell Carcinoma · principal investigator
- N/ANCT05828004 · The SHINE-MDT Randomized Controlled TrialWest China Hospital · completed · Head and Neck Carcinoma, Radiotherapy Side Effects · principal investigator
- Ph1NCT05738447 · Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular CarcinomaWest China Hospital · unknown · Liver Cancer, Hepatocellular Carcinoma · principal investigator
- Ph1NCT05707910 · Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant TumorsWest China Hospital · active not recruiting · Malignant Tumor · principal investigator
- Ph2NCT05659186 · PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid CancerWest China Hospital · unknown · Thyroid Cancer · principal investigator
- Ph2NCT05517330 · Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell CarcinomaWest China Hospital · completed · Head and Neck Cancer · principal investigator
- Ph2NCT05516589 · Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCCWest China Hospital · completed · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph1NCT05299203 · BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)West China Hospital · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph3NCT04414566 · Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal CarcinomaWest China Hospital · unknown · Nasopharyngeal Carcinoma · principal investigator
- Ph2/Ph3NCT04316039 · Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After SurgeryWest China Hospital · recruiting · Low-grade Glioma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:12 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:12 UTC. The ranking covers the 200 most relevant of 295 PubMed records, and a shared surname and initials can bring in a namesake. All 295 on PubMed
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.J Allergy Clin Immunol · 2019576 citationsRCR 29.1
- Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.Nat Med · 2022547 citationsRCR 35.5
- 488 citationsRCR 21.1
- 329 citationsRCR 11.8
- 320 citationsRCR 84.1
- Neoadjuvant Modified FOLFOX6 With or Without Radiation Versus Fluorouracil Plus Radiation for Locally Advanced Rectal Cancer: Final Results of the Chinese FOWARC Trial.J Clin Oncol · 2019294 citationsRCR 12.4
- Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results.Nat Med · 2024211 citationsRCR 22.7
- 174 citationsRCR 5.3
- 164 citationsRCR 10.1
- Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.Lancet Oncol · 2023154 citationsRCR 12.5